Health News Roundup: Vaccines, IPOs, and Drug Prices

This summary covers various health news, including Congo's receipt of mpox vaccines, BioAge Labs filing for a US IPO, a WHO study on mobile phones and brain cancer, Aspen's reliance on GLP-1 drugs, a decision on family planning grants, Eli Lilly's manufacturing deal, Novo Nordisk's Ozempic shortages, Rite Aid's Chapter 11 emergence, Takeda's ADHD drug production, and US negotiations on drug prices.

Following is a summary of current health news briefs.

Congo expects its first delivery of mpox vaccine doses on Thursday and a second on Saturday, as part of efforts to curb a global public health emergency.

BioAge Labs, an obesity therapy startup collaborating with Eli Lilly, filed for a US IPO, aiming to leverage investor enthusiasm.

A WHO-backed study has found no link between mobile phone use and brain cancer, contradicting widespread fears.

Aspen Pharmacare aims to boost profits through GLP-1 drug contracts despite missing growth targets.

The US Supreme Court has allowed a $4.5 million cut in Oklahoma's family planning funding amid an abortion dispute.

Eli Lilly has signed a deal to localize production of its arthritis treatment in Africa with Eva Pharma.

Intermittent shortages of diabetes drug Ozempic in the EU will not affect all member states, according to Novo Nordisk.

Rite Aid will operate as a private company after emerging from Chapter 11 bankruptcy and restructuring.

The DEA has increased the production limit of Takeda's ADHD drug Vyvanse to address a shortage in the US.

US negotiated drug prices remain significantly higher than those in other high-income countries, despite new efforts under the Biden Administration.

(With inputs from agencies.)